HM15421/GC1134A

Small molecule

GGC Biopharma Corp

HM15421/GC1134A is one of 22 small molecule programs targeting Fabry Disease. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Fabry DiseaseActive, not recruiting

Fabry DiseasePhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

36 competitors in Fabry Disease

#DrugCompanyPhaseTrials

Fabrazyme (agalsidase Beta)

Sanofi

Approved

4 2

Active Comparator

Moderna

Phase 3

1 3

Venglustat

Sanofi

Phase 3

1 4

Agalsidase

Sanofi

Approved

8 5

Farxiga

AstraZeneca

Phase 2

1 6

Recombinant Alpha-Galactosidase a

AAssistance Publique - Hôpitaux de Paris

Approved

1 7

Replagal

Takeda

Phase 3

11 8

Galafold

AAmicus Therapeutics

Phase 3

3 9

Agalsidase Alfa

Takeda

Phase 3

6 10

Migalastat Hcl

AAmicus Therapeutics

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 1/2Recruiting

Fabry Disease

NCT06858397

Clinical

Trials by Indication[1]

Fabry Disease1 trial

A proof-of Concept Study to Assess Safety and Tolerability of HM15421/GC1134A in Patients With Fabry Disease

Recruiting·GGC Biopharma Corp·Phase 1/2·NCT06858397·18 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for HM15421/GC1134A. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — HM15421/GC1134A compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for HM15421/GC1134A. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — GC Biopharma Corp company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: GGC Biopharma Corp

HM15421/GC1134A

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Trials by Indication[1]

Fabry Disease1 trial

References

Drug Info

Quick Facts

Related News